These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9698940)

  • 41. Loss of anti-mycobacterial efficacy in mice over time following vaccination with Mycobacterium bovis bacillus Calmette-Guérin.
    Ozeki Y; Hirayama Y; Takii T; Yamamoto S; Kobayashi K; Matsumoto S
    Vaccine; 2011 Sep; 29(40):6881-7. PubMed ID: 21803102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The level and spectrum of antituberculosis antibodies in BCG-vaccinated mice and in mice and rabbits infected with a virulent mycobacterial culture].
    Markov AN; Nikonenko BV; Chernousova LN; Levi DT; Dem'ianenko NV; Litvinov VI
    Probl Tuberk; 1993; (1):43-4. PubMed ID: 8327439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guérin-infected dendritic cells.
    Demangel C; Bean AG; Martin E; Feng CG; Kamath AT; Britton WJ
    Eur J Immunol; 1999 Jun; 29(6):1972-9. PubMed ID: 10382760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection.
    Ryan AA; Spratt JM; Britton WJ; Triccas JA
    Infect Immun; 2007 Jan; 75(1):523-6. PubMed ID: 17074853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis.
    Mahairas GG; Sabo PJ; Hickey MJ; Singh DC; Stover CK
    J Bacteriol; 1996 Mar; 178(5):1274-82. PubMed ID: 8631702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Iron-Rich Diet Decreases the Mycobacterial Burden and Correlates With Hepcidin Upregulation, Lower Levels of Proinflammatory Mediators, and Increased T-Cell Recruitment in a Model of Mycobacterium bovis Bacille Calmette-Guerin Infection.
    Agoro R; Benmerzoug S; Rose S; Bouyer M; Gozzelino R; Garcia I; Ryffel B; Quesniaux VFJ; Mura C
    J Infect Dis; 2017 Oct; 216(7):907-918. PubMed ID: 28973651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice.
    Elias D; Akuffo H; Thors C; Pawlowski A; Britton S
    Clin Exp Immunol; 2005 Mar; 139(3):398-404. PubMed ID: 15730384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Engineering Mycobacteria for the Production of Self-Assembling Biopolyesters Displaying Mycobacterial Antigens for Use as a Tuberculosis Vaccine.
    Lee JW; Parlane NA; Rehm BHA; Buddle BM; Heiser A
    Appl Environ Microbiol; 2017 Mar; 83(5):. PubMed ID: 28087528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis.
    Olleros ML; Vesin D; Lambou AF; Janssens JP; Ryffel B; Rose S; Frémond C; Quesniaux VF; Szymkowski DE; Garcia I
    J Infect Dis; 2009 Apr; 199(7):1053-63. PubMed ID: 19222369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mice that overexpress CC chemokine ligand 2 in their lungs show increased protective immunity to infection with Mycobacterium bovis bacille Calmette-Guérin.
    Schreiber O; Steinwede K; Ding N; Srivastava M; Maus R; Länger F; Prokein J; Ehlers S; Welte T; Gunn MD; Maus UA
    J Infect Dis; 2008 Oct; 198(7):1044-54. PubMed ID: 18694332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Study of a role of artificial mycobacterial particles in the realization of immunological processes in experimental animal tuberculosis].
    Azaev MSh; Lebedev LR; Kuz'micheva GA; Tumanov IuV; Donchenko NA; Tat'kov SI; Nosareva OV; Il'ichev AA
    Probl Tuberk Bolezn Legk; 2007; (2):38-42. PubMed ID: 17419334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct ability to accumulate eosinophils during the inflammatory cellular response to M. bovis BCG in the mouse pleural cavity.
    Werneck-Barroso E; Moura AC; Monteiro MM; Menezes de Lima Júnior O; de Meirelles MN; Henriques MG
    Inflamm Res; 2000 May; 49(5):206-13. PubMed ID: 10893043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cannabinoid 2 receptor agonist β-caryophyllene modulates the inflammatory reaction induced by Mycobacterium bovis BCG by inhibiting neutrophil migration.
    Andrade-Silva M; Correa LB; Candéa AL; Cavalher-Machado SC; Barbosa HS; Rosas EC; Henriques MG
    Inflamm Res; 2016 Nov; 65(11):869-879. PubMed ID: 27379721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.
    Henao-Tamayo M; Obregón-Henao A; Creissen E; Shanley C; Orme I; Ordway DJ
    Clin Vaccine Immunol; 2015 Jan; 22(1):91-8. PubMed ID: 25392011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products.
    Dannenberg AM; Collins FM
    Tuberculosis (Edinb); 2001; 81(3):229-42. PubMed ID: 11466035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune responses in tuberculosis: antibodies and CD4-CD8 lymphocytes with vascular adhesion molecules and cytokines (chemokines) cause a rapid antigen-specific cell infiltration at sites of bacillus Calmette-Guérin reinfection.
    Shigenaga T; Dannenberg AM; Lowrie DB; Said W; Urist MJ; Abbey H; Schofield BH; Mounts P; Sugisaki K
    Immunology; 2001 Apr; 102(4):466-79. PubMed ID: 11328381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison between C57Bl/6 and C57Bl/10 mycobacterial mouse pleurisy with respect to cellular migration and nitric oxide production.
    Rodrigues-Bastos AP; Nascimento CX; Werneck-Barroso E; Cordeiro RS; Henriques Md; Moura AC
    Inflammopharmacology; 2004; 12(4):353-72. PubMed ID: 15901414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs.
    Smith D; Harding G; Chan J; Edwards M; Hank J; Muller D; Sobhi F
    J Biol Stand; 1979 Jul; 7(3):179-97. PubMed ID: 387796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.